5‐Aminolaevulinic acid photodynamic therapy amplifies intense inflammatory response in the treatment of acne vulgaris via CXCL8

• Published in: Experimental dermatology Vol. 30; no. 7; pp. 923 - 931
• Main Authors: Zhang, Linglin, Yang, Jiayi, Liu, Xiaojing, Xu, Detian, Shi, Lei, Liu, Jia, Zeng, Qingyu, Wang, Xiuli
• Format: Journal Article
• Language: English
• Published: Denmark Wiley Subscription Services, Inc 01.07.2021
• Subjects: Acne; acne vulgaris; Acne Vulgaris - drug therapy; ALA‐PDT; Aminolevulinic Acid; CXCL8; Enzyme-Linked Immunosorbent Assay; human sebocytes; Humans; Interleukin-8 - therapeutic use; Leukocytes (neutrophilic); Levulinic Acids - immunology; Levulinic Acids - therapeutic use; Lymphocytes B; Lymphocytes T; Macrophages; microenvironment; Photochemotherapy; Photodynamic therapy; Polymerase Chain Reaction; microenvironment; acne vulgaris; CXCL8; human sebocytes; ALA-PDT
• ISSN: 0906-6705; 1600-0625
• DOI: 10.1111/exd.14357

Acne vulgaris is a chronic inflammatory cutaneous disease. 5‐Aminolaevulinic acid photodynamic therapy (ALA‐PDT) is a novel and effective approach for severe acne vulgaris treatment. However, its specific treatment mechanism still remains unclear. In the present study, we investigated the potential mechanism of how ALA‐PDT regulated intense inflammatory response in acne vulgaris. It appeared that ALA‐PDT suppresses proliferation and lipid secretion of primary human sebocytes. Besides, ALA‐PDT could up‐regulate the expression of CXCL8 in vivo and in vitro, amplifying the inflammatory response by recruiting T cells, B cells, neutrophils and macrophages. We also found that ALA‐PDT elevated the expression of CXCL8 via p38 pathway. SB203580, a p38 pathway inhibitor, decreased the expression of CXCL8 in sebocytes after ALA‐PDT. These findings indicate that ALA‐PDT amplifies the intense inflammatory response in the treatment of acne vulgaris via CXCL8. Our data decipher the mechanism of intense inflammatory response after ALA‐PDT for acne vulgaris.